Regulating open disclosure: a German perspective

The issue of open disclosure has received growing attention from policy-makers, legal experts and academic researchers, predominantly in a number of English-speaking countries. While implementing open disclosure in practice is still an on-going process, open disclosure now forms an integral part of health policy in various American states, the UK, Canada, Australia and New Zealand, with a number of measures having been put in place to encourage open disclosure and to mitigate some of the barriers to such open communication. In contrast, this issue has received little attention in non-English-speaking countries and there is currently no empirical data relating to actual practice or practitioners' attitudes and views in most countries in continental Europe. This article critically examines Germany's current approach to open disclosure. It finds that the issue plays no significant role in German health policy with very limited measures explicitly concerning such communication currently in place. While a number of aspects of the wider regulatory framework appear to be supportive, Germany is still in the early stages of a systematic approach and additional measures are required to further promote open disclosure within the self-governing German healthcare system. This exploration provides an example of a non-English-speaking country's approach to open disclosure and may be of particular interest to neighbouring German-speaking and civil law countries such as Switzerland and Austri

Solution and Solid-State Characterization of Zn(II) Complexes Containing A New Tridentate N\u3csub\u3e2\u3c/sub\u3es Ligand

A new N2S ligand bis(pyridyl)(2-mercapto-1-methylimidazolyl)methane (2, Py2MeImS) has been synthesized and characterized. Treatment of this ligand with bromide and triflate salts of Zn(II) results in the complexes (Py2MeImS)ZnBr2 (3) and [(Py2MeImS)2Zn](OTf)2 (4), respectively. The solid-state structure of (Py2MeImS)ZnBr2 shows bidentate N,N-coordination of Py2MeImS to the zinc ion, with the sulfur atom of the 2-mercaptoimidazole moiety uncoordinated. Two conformers of 3 rapidly interconvert in solution at room temperature, and variable temperature NMR studies and DFT calculations were used to help assign the likely identity of these conformers. In contrast, the crystal structure of [(Py2MeImS)2Zn] (OTf)2 exhibits a zinc ion with a distorted octahedral geometry where the two sulfur atoms of the two ligands are coordinated to the zinc center in a cis-configuration. Even though the cis-isomer (4-cis) is calculated to be lower in energy than the trans-isomer (4-trans), the low temperature 1H NMR spectrum of 4 reveals a single symmetric species that is inconsistent with the cis-isomer observed in the solid-state structure. DFT calculations propose alternative higher energy structures, including a trans-configuration of the coordinated S-atoms of the two Py2MeImS ligands, as well as structures in which the 2-mercaptoimidazole groups are no longer coordinated to the zinc(II) center. These studies provide valuable insight into the potential binding modes of this new ligand and its behavior in solution

Why do patients complain about how health professionals communicate?

While a number of books address the concept of therapeutic communication, i.e. communication between health professionals and their patients, few extend this focus to include communication between health professionals, fewer still address the critical relationship between communication and patient safety. Critical Conversations in Patient Safety bridges that gap

Regulating open disclosure: a German perspective

The issue of open disclosure has received growing attention from policy-makers, legal experts and academic researchers, predominantly in a number of English-speaking countries. While implementing open disclosure in practice is still an on-going process, open disclosure now forms an integral part of health policy in various American states, the UK, Canada, Australia and New Zealand, with a number of measures having been put in place to encourage open disclosure and to mitigate some of the barriers to such open communication. In contrast, this issue has received little attention in non-English-speaking countries and there is currently no empirical data relating to actual practice or practitioners' attitudes and views in most countries in continental Europe. This article critically examines Germany's current approach to open disclosure. It finds that the issue plays no significant role in German health policy with very limited measures explicitly concerning such communication currently in place. While a number of aspects of the wider regulatory framework appear to be supportive, Germany is still in the early stages of a systematic approach and additional measures are required to further promote open disclosure within the self-governing German healthcare system. This exploration provides an example of a non-English-speaking country's approach to open disclosure and may be of particular interest to neighbouring German-speaking and civil law countries such as Switzerland and Austria